This is a news story, published by USA Today, that relates primarily to Vyalev news.
For more Vyalev news, you can click here:
more Vyalev newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from USA Today, you can click here:
more news from USA TodayOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
advanced Parkinson. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Parkinson news, late stage Parkinsons disease news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
advanced ParkinsonsUSA Today
•87% Informative
Injectable drug to ease advanced Parkinson's disease symptoms approved by FDA .
Vyalev , also known as Produodopa , is a 24-hour infusion injected below the skin.
Company said its phase 3 trials showed superior improvement in motor fluctuations compared to an oral drug.
VR Score
87
Informative language
87
Neutral language
71
Article tone
formal
Language
English
Language complexity
64
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
5
Affiliate links
no affiliate links